Search

Your search keyword '"Rudi Pauwels"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Rudi Pauwels" Remove constraint Author: "Rudi Pauwels"
104 results on '"Rudi Pauwels"'

Search Results

1. Field evaluation of a mobile biosafety laboratory in Senegal to strengthen rapid disease outbreak response and monitoring

2. Institut Pasteur Dakar Mobile Lab: Part of the Solution to Tackle COVID Pandemic in Senegal, a Model to Be Exploited

Catalog

Books, media, physical & digital resources

3. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data.

4. Field evaluation of a mobile biosafety laboratory in Senegal to strengthen rapid disease outbreak response and monitoring

5. The Status of Breast Pathology around the Globe

6. Health Systems

7. Realistic Hope

8. Realistic Hope

9. Aspects of successful drug discovery and development

10. TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments

11. Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus

12. TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

13. 4-Benzyl- and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones, a New Family of Potent Anti-HIV Agents: Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains

14. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

15. Encoding microcarriers by spatial selective photobleaching

16. [Untitled]

17. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues

18. Charge modification of plasma and milk proteins results in antiviral active compounds

19. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting

20. Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure

21. Betulinic Acid Derivatives: A New Class of Human Immunodeficiency Virus Type 1 Specific Inhibitors with a New Mode of Action

22. Synthesis and Structure−Activity Relationships of Phenylenebis(methylene)- Linked Bis-tetraazamacrocycles That Inhibit Human Immunodeficiency Virus Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams

23. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution

24. Automated techniques in biotechnology

25. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs

26. Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase

27. Activity of a Sulfated Polysaccharide Extracted from the Red Seaweed Aghardhiella Tenera against Human Immunodeficiency Virus and Other Enveloped Viruses

28. A time-of-drug addition approach to target identification of antiviral compounds

29. Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect

30. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

31. ChemInform Abstract: Betulinic Acid Derivatives: A New Class of Human Immunodeficiency Virus Type 1 Specific Inhibitors with a New Mode of Action

32. ChemInform Abstract: Betulinic Acid Derivatives: A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1 Entry

33. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335

34. TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication

35. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages

36. Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives

37. Differential Activity of Polyanionic Compounds and Castanospermine against HIV Replication and HIV-Induced Syncytium Formation Depending on Virus Strain and Cell Type

38. Specific HIV-1 Reverse Transcriptase Inhibitors

39. Screening of Compounds for Activity against HIV: A Collaborative Study

40. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates

41. Antiviral Activity of low-MW Dextran Sulphate (Derived from dextran MW 1000) Compared to Dextran Sulphate Samples of Higher MW

42. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives

43. Targeting of antiviral drugs to T4-lymphocytes

44. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1

45. Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells

46. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

48. New Reverse Transcriptase Inhibitors in Development

49. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

50. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)